Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.
ImmunoCOVID
1 other identifier
observational
1,500
1 country
1
Brief Summary
A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 22, 2020
CompletedFirst Submitted
Initial submission to the registry
May 6, 2020
CompletedFirst Posted
Study publicly available on registry
May 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 21, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 21, 2021
CompletedMay 20, 2020
March 1, 2020
12 months
May 6, 2020
May 18, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting
To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year
1 year
Secondary Outcomes (3)
Number of children/adults tested positive for COVID19
1 year
Number of children/adults admitted in hospital because of COVID19
1 year
To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children
1 year
Interventions
A weekly questionnaire will be filled in
Eligibility Criteria
Children and adults vulnerable for infection due to a condition or to medication they are using.
You may qualify if:
- Children part: Parent of immunosuppressed patient aged \<16 years or immunosuppressed patient aged 16-17 years
- Adult part: Immunosuppressed patient aged \>17 years
- Family or themselves able to complete the questionnaire which will be in English (due to current resources available translation will not be possible)
- Reliable access to the internet
You may not qualify if:
- Unable to understand English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Southampton NHS Foundation Trustlead
- Cambridge University Hospitals NHS Foundation Trustcollaborator
- Alder Hey Children's Hospitalcollaborator
- Birmingham Children's Hospitalcollaborator
- Bradford Royal Infirmarycollaborator
- Bristol Royal Hospital for Childrencollaborator
- Cardiff and Vale University Health Boardcollaborator
- Great North Children's Hospitalcollaborator
- Great Ormond Street Hospital for Children NHS Foundation Trustcollaborator
- Oxford University Hospitals NHS Trustcollaborator
- Leeds Teaching Hospitals NHS Trustcollaborator
- Norfolk and Norwich University Hospitals NHS Foundation Trustcollaborator
- Nottingham Children's Hospitalcollaborator
- Royal Alexandra Children's Hospitalcollaborator
- Royal Hospital for Sick Children, Glasgowcollaborator
- Royal Manchester Children's Hospitalcollaborator
- Royal Marsden NHS Foundation Trustcollaborator
- Northern Care Alliance NHS Groupcollaborator
- Royal Sussex County Hospitalcollaborator
- Sheffield Children's NHS Foundation Trustcollaborator
- St George's University Hospital National Health Service Foundation Trustcollaborator
- Swansea Bay University Health Boardcollaborator
- University College London Hospitalscollaborator
- University Hospitals Coventry and Warwickshire National Health Service Trustcollaborator
- East Lancashire Hospitals National Health Service Trustcollaborator
- Imperial College Healthcare National Health Service Trustcollaborator
- National Heatlh Service Ayrshire and Arrancollaborator
Study Sites (1)
University Hospital Southampton NHS FT
Southampton, Hampshire, SO16 6YD, United Kingdom
Related Publications (1)
Shaunak M, Patel R, Driessens C, Mills L, Leahy A, Gbesemete D, Owens DR, Lucas JS, Faust SN, de Graaf H; ImmunoCOVID19 study group. COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. BMJ Open. 2021 Mar 17;11(3):e044899. doi: 10.1136/bmjopen-2020-044899.
PMID: 33737439DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hans de Graaf, MD
University Hospital Southampton NHS Foundation Trust
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 6, 2020
First Posted
May 11, 2020
Study Start
March 22, 2020
Primary Completion
March 21, 2021
Study Completion
March 21, 2021
Last Updated
May 20, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share